Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $1.25, $0.46 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $6.49 billion versus the consensus estimate of $6.85 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2022 EPS of $7.90-$8.05, versus the consensus of $8.08.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.